Some Lucentis patients have had detached retinas and serious infections inside the eye. If the eye becomes red, sensitive to light, or painful, or if there is a change in vision, patients should call ...

The Genentech Inc. eye drug Lucentis performed well in a late-stage study of patients with diabetic macular edema — a treatment that could be rejected in the United Kingdom — but the real insight ...

ZURICH, May 4 (Reuters) - Swiss drugmaker Novartis AG said on Wednesday a new study showed that its Lucentis eye drug is safer than cancer drug Avastin for treating macular degeneration. Novartis said ...

Ranibizumab implants approved by FDA for DME offer a more convenient treatment schedule, reducing injection frequency significantly. The phase 3 Pagoda study showed noninferior visual acuity with ...

FDA has announced it has approved Lucentis (ranibizumab injection) for the treatment of diabetic macular edema, according to a news release. DME is a sight-threatening eye disease that occurs in ...

NEW YORK, Nov 22 (Reuters) - Regeneron Pharmaceuticals Inc's treatment for the leading cause of blindness in the elderly was as effective and safe in two late-stage trials as Roche Holding AG's $3 ...

IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more.

(RTTNews) - Teva Pharmaceutical Industries Ltd (TEVA) announced the UK Medicines & Healthcare Regulatory Agency has decided to grant a licence for Ongavia, a biosimilar to Lucentis (ranibizumab), an ...

The approval of Cimerli was based on a comprehensive analytical, preclinical and clinical program including the phase 3 COLUMBUS-AMD study. Cimerli, a vascular endothelial growth factor inhibitor, is ...